Familial Mediterranean fever

1. Siegal S. Benign paroxysmal peritonitis. Gastroenterology. 1949 Feb;12(2):234-47.[Abstract]

2. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford). 2004 Apr;43(4):410-5.[Abstract][Full Text]

3. Zaks N, Shinar Y, Padeh S, et al. Analysis of the three most common MEFV mutations in 412 patients with familial Mediterranean fever. Isr Med Assoc J. 2003 Aug;5(8):585-8.[Abstract][Full Text]

4. Tunca M, Akar S, Onen F, et al; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005 Jan;84(1):1-11.[Abstract]

5. Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019 Aug;78(8):1025-32.[Abstract][Full Text]

6. Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med. 1967 Aug;43(2):227-53.[Abstract]

7. Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997 Aug;156(8):619-23.[Abstract]

8. Blum A, Gafni J, Sohar E, et al. Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF): further evidence of its genetic nature. Ann Intern Med. 1962 Nov;57:795-9.[Abstract]

9. Balci B, Tinaztepe K, Yilmaz E, et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant. 2002 Nov;17(11):1921-3.[Abstract][Full Text]

10. Melikoğlu M, Ozdoğan H, Korkmaz C, et al. A survey of phenotype II in familial Mediterranean fever. Ann Rheum Dis. 2000 Nov;59(11):910-3.[Abstract][Full Text]

11. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998 Feb 28;351(9103):659-64.[Abstract]

12. Özen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):254-60.[Abstract]

13. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020 Nov 3;50(si-2):1591-610.[Abstract][Full Text]

14. Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):77-80.[Abstract]

15. Tchernitchko D, Moutereau S, Legendre M, et al. MEFV analysis is of particularly weak diagnostic value for recurrent fevers in Western European Caucasian patients. Arthritis Rheum. 2005 Nov;52(11):3603-5.[Abstract][Full Text]

16. Majeed HA, Rawashdeh M, el-Shanti H, et al. Familial Mediterranean fever in children: the expanded clinical profile. QJM. 1999 Jun;92(6):309-18.[Abstract][Full Text]

17. Gershoni-Baruch R, Brik R, Lidar M, et al. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol. 2003 Feb;30(2):308-12.[Abstract]

18. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997 Aug 22;90(4):797-807.[Abstract]

19. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997 Sep;17(1):25-31.[Abstract]

20. Gershoni-Baruch R, Shinawi M, Leah K, et al. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet. 2001 Aug;9(8):634-7.[Abstract][Full Text]

21. Brik R, Litmanovich D, Berkowitz D, et al. Incidence of familial Mediterranean fever (FMF) mutations among children of Mediterranean extraction with functional abdominal pain. J Pediatr. 2001 May;138(5):759-62.[Abstract]

22. Gershoni-Baruch R, Brik R, Shinawi M, et al. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet. 2002 Feb;10(2):145-9.[Abstract][Full Text]

23. Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 2004 Jun;5(4):289-93.[Abstract]

24. Akar N, Akar E, Yalçinkaya F. E148Q of the MEFV gene causes amyloidosis in familial Mediterranean fever patients. Pediatrics. 2001 Jul;108(1):215.[Abstract]

25. Sugiura T, Kawaguchi Y, Fujikawa S, et al. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. Mod Rheumatol. 2008;18(1):57-9.[Abstract]

26. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015 Apr;74(4):635-41.[Abstract]

27. Topaloglu R, Batu ED, Yıldız Ç, et al. Familial Mediterranean fever patients homozygous for E148Q variant may have milder disease. Int J Rheum Dis. 2018 Oct;21(10):1857-62.[Abstract]

28. Tirosh I, Yacobi Y, Vivante A, et al. Clinical significance of E148Q heterozygous variant in paediatric familial Mediterranean fever. Rheumatology (Oxford). 2021 Nov 3;60(11):5447-51.[Abstract]

29. Arici ZS, Romano M, Piskin D, et al. Evaluation of E148Q and concomitant AA amyloidosis in patients with familial Mediterranean fever. J Clin Med. 2021 Aug 10;10(16):3511.[Abstract][Full Text]

30. Kastner DL. Familial Mediterranean fever: the genetics of inflammation. Hosp Pract (Minneap). 1998 Apr 15;33(4):131-4, 139-40, 143-6 passim.[Abstract]

31. Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM. 2000 Apr;93(4):217-21.[Abstract][Full Text]

32. Aldea A, Campistol JM, Arostegui JI, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A. 2004 Jan 1;124A(1):67-73.[Abstract][Full Text]

33. Stoffels M, Szperl A, Simon A, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis. 2014 Feb;73(2):455-61.[Abstract]

34. Kone-Paut I, Hentgen V, Guillaume-Czitrom S, et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford). 2009 Jul;48(7):840-2.[Abstract][Full Text]

35. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009 Jun;60(6):1862-6.[Abstract][Full Text]

36. Moradian MM, Sarkisian T, Ajrapetyan H, et al. Genotype-phenotype studies in a large cohort of Armenian patients with familial Mediterranean fever suggest clinical disease with heterozygous MEFV mutations. J Hum Genet. 2010 Jun;55(6):389-93.[Abstract]

37. Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev. 2012 Nov;12(1):31-7.[Abstract]

38. Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. J Med Genet. 2013 Jun;50(6):349-59.[Abstract][Full Text]

39. Federici S, Calcagno G, Finetti M, et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis. 2012 Dec;71(12):1961-5.[Abstract]

40. Karadag O, Tufan A, Yazisiz V, et al. The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int. 2013 Apr;33(4):893-7.[Abstract]

41. Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014 Apr;73(4):662-7.[Abstract]

42. Pras E, Aksentijevich I, Gruberg L, et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med. 1992 Jun 4;326(23):1509-13.[Abstract][Full Text]

43. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7.[Abstract][Full Text]

44. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007 Aug;14(8):1457-66.[Abstract][Full Text]

45. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009 Sep;146(5):467-78.[Abstract][Full Text]

46. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R86-98.[Abstract][Full Text]

47. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature. 2014 Sep 11;513(7517):237-41.[Abstract]

48. Ben-Zvi I, Danilesko I, Yahalom G, et al. Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. Isr Med Assoc J. 2012 Apr;14(4):221-4.[Abstract][Full Text]

49. Sarkisian T, Ajrapetyan H, Shahsuvaryan G. Molecular study of FMF patients in Armenia. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):113-6.[Abstract]

50. Kone Paut I, Dubuc M, Sportouch J, et al. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford). 2000 Nov;39(11):1275-9.[Abstract]

51. Dewalle M, Domingo C, Rozenbaum M, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever. Eur J Hum Genet. 1998 Jan;6(1):95-7.[Abstract][Full Text]

52. Grateau G. The relation between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol. 2000 Jan;12(1):61-4.[Abstract]

53. Sidi G, Shinar Y, Livneh A, et al. Protracted febrile myalgia of familial Mediterranean fever: mutation analysis and clinical correlations. Scand J Rheumatol. 2000;29(3):174-6.[Abstract]

54. Grateau G, Pêcheux C, Cazeneuve C, et al. Clinical versus genetic diagnosis of familial Mediterranean fever. QJM. 2000 Apr;93(4):223-9.[Abstract][Full Text]

55. Guzel F, Romano M, Keles E, et al. Next generation sequencing based multiplex long-range PCR for routine genotyping of autoinflammatory disorders. Front Immunol. 2021 Jun 9;12:666273.[Abstract][Full Text]

56. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol. 2003 Sep;30(9):2014-8.[Abstract]

57. Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006 Jun;45(6):746-50.[Abstract][Full Text]

58. Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation? Arthritis Rheum. 2009 Jun;60(6):1575-7.[Abstract][Full Text]

59. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007 May;56(5):1706-12.[Abstract][Full Text]

60. Simon A, van der Meer JW, Vesely R, et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford). 2006 Mar;45(3):269-73.[Abstract][Full Text]

61. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 Oct;40(10):1879-85.[Abstract]

62. Demirkaya E, Saglam C, Turker T, et al. Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol. 2016 Jan;43(1):154-60.[Abstract]

63. Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009 Apr;48(4):395-8.[Abstract][Full Text]

64. Padeh S, Livneh A, Pras E, et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol. 2010 Apr;37(4):865-9.[Abstract]

65. Romano M, Piskin D, Berard RA, et al. Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis. Sci Rep. 2020 Oct 27;10(1):18374.[Abstract][Full Text]

66. Sahin S, Romano M, Guzel F, et al. Assessment of surrogate markers for cardiovascular disease in familial Mediterranean fever-related amyloidosis patients homozygous for M694V mutation in MEFV gene. Life (Basel). 2022 Apr 25;12(5):631.[Abstract][Full Text]

67. Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum. 2007 Dec;37(3):182-8.[Abstract]

68. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972 Dec 21;287(25):1302.[Abstract]

69. Demirkaya E, Erer B, Ozen S, et al. Efficacy and safety of treatments in familial Mediterranean fever: a systematic review. Rheumatol Int. 2016 Mar;36(3):325-31.[Abstract]

70. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000 Sep;14(3):477-98.[Abstract]

71. Brik R, Shinawi M, Kasinetz L, et al. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001 Jun;44(6):1416-9.[Abstract][Full Text]

72. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthitis Rheum. 1996 Dec;26(3):612-27.[Abstract]

73. Rimar D, Rosner I, Rozenbaum M, et al. Familial Mediterranean fever: an association with non-alcoholic fatty liver disease. Clin Rheumatol. 2011 Jul;30(7):987-91.[Abstract]

74. Tweezer-Zaks N, Doron-Libner A, Weiss P, et al. Familial Mediterranean fever and cryptogenic cirrhosis. Medicine (Baltimore). 2007 Nov;86(6):355-62.[Abstract]

75. Barzilai A, Langevitz P, Goldberg I, et al. Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. J Am Acad Dermatol. 2000 May;42(5 Pt 1):791-5.[Abstract]

76. Feld O, Yahalom G, Livneh A. Neurologic and other systemic manifestations in FMF: published and own experience. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):119-33.[Abstract]

77. Lossos A, Eliashiv S, Ben-Chetrit E, et al. Optic neuritis associated with familial Mediterranean fever. J Clin Neuroophthalmol. 1993 Jun;13(2):141-3.[Abstract]

78. Dabestani A, Noble LM, Child JS, et al. Pericardial disease in familial Mediterranean fever: an echocardiographic study. Chest. 1982 May;81(5):592-5.[Abstract]

79. Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM. 1997 Oct;90(10):643-7.[Abstract]

80. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr. 2010 Feb;99(2):178-84.[Abstract]

81. Thomas KT, Feder HM Jr, Lawton AR, et al. Periodic fever syndrome in children. J Pediatr. 1999 Jul;135(1):15-21.[Abstract]

82. Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum. 2008 Jun;58(6):1823-32.[Abstract][Full Text]

83. Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes. Pediatr Infect Dis J. 2007 Apr;26(4):353-4.[Abstract]

84. Frenkel J, Kuis W. Overt and occult rheumatic diseases: the child with chronic fever. Best Pract Res Clin Rheumatol. 2002 Jul;16(3):443-69.[Abstract]

85. Farasat S, Aksentijevich I, Toro J. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. 2008 Mar;144(3):392-402.[Abstract]

86. Masson C, Simon V, Hoppe E, et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine. 2004 Jul;71(4):284-90.[Abstract]

87. Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. Q J Med. 1982;51(204):469-80.[Abstract]

88. Samuels J, Ozen S. Familial Mediterranean fever and other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol. 2006 Jan;18(1):108-17.[Abstract]

89. Kastner D. Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program. 2005:74-81.[Abstract][Full Text]

90. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004 Feb;33(4):273-82.[Abstract]

91. Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994 Dec;37(12):1804-11.[Abstract]

92. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun;38(6):411-9.[Abstract]

93. Majeed HA, Al-Qudah AK, Qubain H, et al. The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum. 2000 Oct;30(2):138-43.[Abstract]

94. Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011 Oct;41(2):265-71.[Abstract]

95. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16;157(8):533-41.[Abstract]

96. Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011 Mar;38(3):516-8.[Abstract]

97. Kuemmerle-Deschner JB, Gautam R, George AT, et al. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever. Rheumatology (Oxford). 2020 Oct 1;59(10):2711-24.[Abstract][Full Text]

98. Poddighe D, Romano M, Garcia-Bournissen F, et al. Conventional and novel therapeutic options in children with familial Mediterranean fever: a rare autoinflammatory disease. Br J Clin Pharmacol. 2022 Jun;88(6):2484-99.[Abstract]

99. Kacar M, Savic S, van der Hilst JCH. The efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature. J Inflamm Res. 2020 Mar 9;13:141-49.[Abstract]

100. Yin X, Tian F, Wu B, et al. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev. 2022 Mar 29;(3):CD010893.[Abstract][Full Text]

101. Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May;72(5):678-85.[Abstract]

102. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013 Dec;43(3):387-91.[Abstract]

103. Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011 Oct;17(7):358-62.[Abstract]

104. Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S1-3.[Abstract]

105. Polat A, Acikel C, Sozeri B, et al. Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever - a randomized controlled noninferiority trial. Arthritis Res Ther. 2016 Apr 7;18:85.[Abstract][Full Text]

106. Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991 Feb;20(4):241-6.[Abstract]

107. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83.[Abstract]

108. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51.[Abstract]

109. Sayarlioglu M, Sayarlioglu H, Ozen S, et al. Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann Pharmacother. 2003 Dec;37(12):1821-4.[Abstract]

110. Colak S, Tekgoz E, Cinar M, et al. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: a retrospective study of 15 patients. Mod Rheumatol. 2021 Jan;31(1):223-25.[Abstract]

111. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016 Apr;75(4):644-51.[Abstract]

112. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R86-98.[Abstract][Full Text]

113. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007 Feb;119(2):e474-83.[Abstract]

114. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever: a double-blind trial. N Engl J Med. 1974 Oct 31;291(18):934-7.[Abstract]

115. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, et al. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004 Oct;34(2):549-52.[Abstract]

116. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013 Dec;43(3):387-91.[Abstract]

117. Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986 Apr 17;314(16):1001-5.[Abstract]

118. Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum. 1997 Oct;27(2):67-72.[Abstract]

119. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, et al. The outcome of pregnancy in the wives of men with familial Mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004 Oct;34(2):549-52.[Abstract]

120. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003 Oct;62(10):916-9.[Abstract]

121. Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum. 1996 Jul;39(7):1213-7.[Abstract]

122. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken). 2010 Feb;62(2):143-8.[Abstract][Full Text]

123. Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int. 2011 Oct;31(10):1263-74.[Abstract]

124. Ozçakar ZB, Yalçınkaya F. Vascular comorbidities in familial Mediterranean fever. Rheumatol Int. 2011 Oct;31(10):1275-81.[Abstract]

125. Espinosa G, Arostegui JI, Plaza S, et al. Behçet's disease and hereditary periodic fever syndromes: casual association or causal relationship? Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S64-6.[Abstract]

126. Imirzalioglu N, Dursun A, Tastan B, et al. MEFV gene is a probable susceptibility gene for Behçet's disease. Scand J Rheumatol. 2005;34(1):56-8.[Abstract]

127. Schwartz T, Langevitz P, Zemer D, et al. Behçet's disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum. 2000 Apr;29(5):286-95.[Abstract]

128. Livneh A, Aksentijevich I, Langevitz P, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behçet's disease (FMF-BD). Eur J Hum Genet. 2001 Mar;9(3):191-6.[Abstract][Full Text]

129. Korkmaz C, Kaşifoğlu T. Changes in the liver function tests during the attacks of familial Mediterranean fever. Rheumatol Int. 2007 Feb;27(4):395-8.[Abstract]

130. Erer B, Demirkaya E, Ozen S, et al. What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int. 2016 Apr;36(4):483-7.[Abstract]

131. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37.[Abstract][Full Text]

132. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14.[Abstract]

133. Piskin D, Arici ZS, Konukbay D, et al. Number of episodes can be used as a disease activity measure in familial Mediterranean fever. Front Pediatr. 2022 Apr 27;10:822473.[Abstract][Full Text]

134. Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016 Jun;75(6):1051-6.[Abstract]